• Korea United Pharm posted a third-quarter 2026 net loss of KRW 7.02 billion versus a year-earlier profit of KRW 13.54 billion.
• Operating profit fell 77.4% year over year to KRW 2.82 billion, down 78.8% from the previous quarter.
• Revenue declined 8.5% year over year to KRW 68.07 billion, down 11.9% sequentially.
• For January-September 2026, net profit rose 63.2% year over year to KRW 44.68 billion.
• Nine-month operating profit dropped 26.1% to KRW 27.38 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korea United Pharm. Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030801304), on October 30, 2026, and is solely responsible for the information contained therein.